Failure of actinomycin D entrapped in liposomes to prolong survival in renal cell adenocarcinoma-bearing mice.
The potential prolongation of survival of actinomycin D entrapped in liposomes was examined in Balb C/Cr mice inoculated intrarenally with renal cell adenocarcinoma. There were five groups of animals: group A, a control group, received phosphate-buffered saline 0.3 cm3 i.p.; group B received free actinomycin D 300 micrograms/kg i.p.; group C received liposomes containing actinomycin D 300 micrograms/kg i.p.; group D received a mixture of free actinomycin D 300 micrograms/kg and empty liposomes i.p.; group E received empty liposomes i.p. The best median survival was of group D (free drug) - 54 days followed by group C (liposome entrapped actinomycin D) 45.2 days and group E (a mixture of free and entrapped actinomycin D) - 42 days. In vitro studies utilizing cell lines obtained from the tumor showed no statistical difference in ID50 or in cytotoxicity between the cells treated with free actinomycin D and those treated with liposomes containing drug.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D002478:Cells, Cultured; D003609:Dactinomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D006085:Graft Survival / Q000187:drug effects; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008081:Liposomes / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D014184:Transplantation, Homologous
D008081:Liposomes; D003609:Dactinomycin